Disease Models & MechanismsCancer BiologyPeer-reviewed journal article
Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis
S.-H. Kim, R. P. Redvers, L. H. Chi, X. Ling, A. J. Lucke, R. C. Reid, D. Fairlie, A. C. Baptista Moreno Martin, R. L. Anderson, D. Denoyer, N. Pouliot
Abstract
Breast cancer brain metastasis remains largely incurable. While several mouse models have been developed to investigate the genes and mechanisms regulating breast cancer brain metastasis, these models often lack clinical relevance since they require the use of immune-compromised mice and/or are poorly metastatic to brain from the mammary gland. We describe the development and characterisation of an aggressive brain metastatic variant of the 4T1 syngeneic model (4T1Br4) that spontaneously metastasises to multiple organs, but is selectively more metastatic to the brain from the mammary gland than parental 4T1 tumours. By immunohistochemistry, 4T1Br4 tumours and brain metastases display a triple negative phenotype, consistent with the high propensity of this breast cancer subtype to spread to brain. In vitro assays indicate that 4T1Br4 cells have an enhanced ability to adhere to or migrate across a brain-derived endothelial monolayer and greater invasive response to brain-derived soluble factors compared to 4T1 cells. These properties are likely to contribute to the brain-selectivity of 4T1Br4 tumours. Expression profiling and gene set enrichment analyses demonstrate the clinical relevance of the 4T1Br4 model at the transcriptomic level. Pathway analyses implicate tumour-intrinsic immune regulation and vascular interactions in successful brain colonisation, revealing potential therapeutic targets. Evaluation of two histone deacetylase inhibitors, SB939 and 1179.4b, shows partial efficacy against 4T1Br4 metastasis to brain and other sites in vivo and potent radio-sensitising properties in vitro. The 4T1Br4 model provides a clinically relevant tool for mechanistic studies and to evaluate novel therapies against brain metastasis.\n\nSUMMARY STATEMENTWe introduce a new syngeneic mouse model of spontaneous breast cancer brain metastasis, demonstrate its phenotypic, functional and transcriptomic relevance to human TNBC brain metastasis and test novel therapies.
- organism: mouse
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- RET Receptor Tyrosine Kinase Promotes Breast Cancer Metastasis to the Brain and RET Inhibitors Pralsetinib and Selpercatinib Suppress Breast Cancer Brain Metastases
Angelina T. Regua, Shivani Bindal, … Hui‐Wen Lo·Cell Death and DiseasePeer-reviewed·Jun 1, 2026
- Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis
J. D. Mackert, E. R. Stirling, … D. R. Soto-Pantoja·bioRxiv·Jul 25, 2023
- Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages.
Xiaoqing Cheng, Khooshbu Kantibhai Patel, … Ron Bose·bioRxiv·Jun 17, 2025
- Syndecan-1 facilitates breast cancer metastasis to the brain
M. R. Sayyad, M. Puchalapalli, … J. E. Koblinski·bioRxiv·Mar 5, 2019
- Immunophenotyping of HER4/YAP axis in breast cancer brain metastasis
P. Kalita-de Croft, M. Lim, … S. R. Lakhani·bioRxiv·Jan 29, 2020
- Targeting RET in Brain Metastases from Estrogen Receptor Positive Breast Cancer
Simeng Liu, Geoffrey L. Pecar, … Adrian V. Lee·bioRxiv·Apr 4, 2025